The Safety and Efficacy of Perioperative Dexmedetomidine in Cardiac Surgery Patients - A Pilot Trial

Phase 2

Completed

• Conditions: Combined coronary artery bypass graft surgery and valve surgery; Valve surgery; Aortic arch surgery; Cardiovascular - Other cardiovascular diseases; Anaesthesiology - Anaesthetics

• Registration Number: ACTRN12615001358538
• Lead Sponsor: Monash Medical Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-12-15
• Study Completion: 2017-02-03
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1) Older than 18 years of age
2) Patients undergoing combined cardiac surgery (CABG + valve) or (Double valve) or major aortic arch surgery
3) GFR<60

Exclusion Criteria

1) Patients <18 years
2) CKD stage IV (eGFR<20 ml/min/1.72m2) or Dialysis dependent patients
3) Planned off pump cardiac surgery, salvage surgery, extracorporeal support, high grade AV block in the absence of pacemaker
4) Allergy to dexmedetomidine
5) Severe hepatic impairment defined as Child C liver disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This is a composite primary outcome of number of days home, alive and disability free at 28 days following surgery. A research coordinator will call the participants to check that they are still alive and how long they have been at home. If a patient is alive, a number of pre-written questions to assess the quality of life of the participant will be asked by the research coordinator.[28 days post hospital discharge]